SCHEMBL6405469

SCHEMBL6405469

O=C1CCN(Cc2ncccc2O)CC1C(c1ccccc1)c1ccccc1

nearest known ligand 0.62

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
TACR1 P25103 19/20 0.62
CYP2C19 P33261 1/20 0.49
HIF1A Q16665 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6406529 0.82 TACR1 (0.60) TACR1
SCHEMBL6409780 0.82 TACR1 (0.82) TACR1
SCHEMBL6410331 0.81 TACR1 (0.68) TACR1
SCHEMBL6411370 0.78 TACR1 (1.00) TACR1
SCHEMBL6405717 0.77 TACR1 (0.82) TACR1
SCHEMBL6405882 0.77 TACR1 (0.77) TACR1
SCHEMBL6408012 0.74 TACR1 (0.77) TACR1
SCHEMBL24569015 0.74 CYP2C19 (0.83) CYP2C19HIF1A
SCHEMBL24569006 0.74 CYP2C19 (0.83) CYP2C19HIF1A
SCHEMBL6408258 0.74 TACR1 (1.00) TACR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050038072-A1 Nitrogeneous cyclic ketone derivative, process for producing the same, and use TAKEDA CHEMICAL INDUSTRIES, LTD. 2005-02-17 US disclosed
EP-1460062-A1 NITROGENOUS CYCLIC KETONE DERIVATIVE, PROCESS FOR PRODUCING THE SAME, AND USE Takeda Chemical Industries, Ltd. (JP) 2004-09-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050038072-A1 Nitrogeneous cyclic ketone derivative, process for producing the same, and use BDKRB1, BDKRB2, TACR1 TACR1 3/4885CYP2C19 866/4885HIF1A 315/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.